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Ferritin is a spherical molecule composed of 24 subunits of two
types, ferritin H chain (FHC) and ferritin L chain (FLC). Ferritin stores
iron within cells, but it also circulates and binds speciﬁcally and
saturably to a variety of cell types. For most cell types, this binding
can be mediated by ferritin composed only of FHC (HFt) but not by
ferritin composedonlyof FLC (LFt), indicating thatbindingof ferritin
to cells is mediated by FHC but not FLC. By using expression cloning,
we identiﬁed human transferrin receptor-1 (TfR1) as an important
receptor for HFt with little or no binding to LFt. In vitro, HFt can be
precipitated by soluble TfR1, showing that this interaction is not
dependent on other proteins. Binding of HFt to TfR1 is partially
inhibited by diferric transferrin, but it is hindered little, if at all, by
HFE. After binding of HFt to TfR1 on the cell surface, HFt enters both
endosomes and lysosomes. TfR1 accounts for most, if not all, of the
binding of HFt to mitogen-activated T and B cells, circulating retic-
ulocytes, and all cell lines that we have studied. The demonstration
that TfR1 can bind HFt as well as Tf raises the possibility that this
dual receptor function may coordinate the processing and use of
iron by these iron-binding molecules.
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Iron is essential for life in most organisms (1–3). Soluble iron,however, accelerates the generation of reactive oxygen species
(ROS) from H2O2, and it is therefore toxic to cells (4). Ferritin
allows the storage of iron in high concentration and without access
to the substrates that generate ROS (5–7).
Ferritin is a spherical molecule composed of 24 subunits, a
mixture of ferritin H chain (FHC) and ferritin L chain (FLC).
FHC is named for its initial isolation from heart, whereas FLC is
named for its initial isolation from liver (1). In humans, FHC is
also heavier (∼21 kDa) than FLC (∼19 kDa), and the ferritin
subunits are sometimes referred to as heavy and light ferritin,
respectively (1). The ratio of FHC to FLC within ferritin varies
from species to species and from organ to organ, and it also
varies in response to inﬂammation. FHC and FLC are highly
homologous, and they can form a ferritin sphere in any pro-
portion; however, only FHC can oxidize Fe2+ to Fe3+, and FHC
facilitates the accumulation of iron within ferritin (8). Within
ferritin, iron is stored in mineral form as ferrihydrite, and
nucleation of ferrihydrite is promoted by FLC (7, 9).
In addition to its role in storing iron within cells, ferritin also
circulates. Here, its role is uncertain, but ferritin can bind to a
variety of cell types in a saturable manner. These include lympho-
cytes, placental microvilli, and erythroid precursors (10–17). On
most cell types, binding has been observed for ferritin composed
only of FHC (HFt) but not for ferritin composedonly of FLC (LFt).
Studies of liver cells, however, have suggested a second receptor
that binds both HFt and LFt (17). The erythroleukemic cell line
K562 binds HFt with an apparent equilibrium association of ∼3 ×
10−8 L/mol and anestimated 20,000 receptors per cell (12), whereas
MOLT-4T cells bindHFtwith an apparent equilibrium association
constant of ∼6.5 × 10−7 L/mol and ∼10,000 receptors sites per cell;
subsequently, they endocytose HFt (13). Activated fresh lympho-
cytes also bind HFt (16), as do erythroid precursors, in which the
subsequent endocytosis of HFt permits sufﬁcient uptake of iron to
produce hemoglobin (Hb) (18, 19). Although transferrin (Tf) is the
usual and dominant source of iron for erythropoiesis, ferritin can
provide sufﬁcient iron for this to occur in the absence of Tf (19, 20).
In studies of mouse cells, we recently showed that T cell immu-
noglobulin and mucin domain protein-2 (TIM-2) serves as an
endocytosing receptor for HFt but not LFt. TIM-2 is expressed on
activated lymphocytes, but it is also expressed outside the hema-
topoietic system on bile-duct epithelial cells and kidney tubular
epithelial cells (21). Mature rat oligendrocytes also express TIM-2,
and they use it as a primary source of intracellular HFt (22). TIM-2
is not, however, expressed in humans (23).
In the studies presented here, we use expression cloning to
identify human transferrin receptor-1 (TfR1) as an endocytosing
cell-surface receptor forHFt.We show that bindingofHFt toTfR1
occurs independently of Tf or the hemochromatosis-associated
protein HFE, and instead it is partially blocked by diferric Tf.
Binding of HFt to TfR1 results in the uptake of HFt into endo-
somes and lysosomes. Finally, by using an mAb that blocks the
binding of HFt to TfR1, we show that TfR1 accounts for most
binding of HFt to cells, including mitogen-activated lymphocytes
and circulating reticulocytes.
Results
Molecular Cloning of Receptors for Human HFt Identiﬁes TfR1. To
deﬁne human receptors for HFt, we ﬁrst screened a panel of human
cell lines for saturablebindingof recombinanthumanHFt.HFtbound
the humanBcell line 721.221 but not themousepro-B cell lineBa/F3.
We, therefore, expressed a cDNA library from 721.221 cells in Ba/F3
cells and screened for binding ofHFt; 8 of>100 clones obtainedwere
sequenced in full, and all encoded TfR1. As an example, binding of
HFt and anti-TfR mAb to one clone is shown in Fig. 1A.
To conﬁrm that binding of HFt was mediated by TfR1, we ex-
pressed the cDNA for TfR1 inBa/F3 cells. TheseBa/F3.hTfR1 cells
boundHFt (Fig. 1B andC) but not detectable amounts of LFt (Fig.
S1). At concentrations above 50 μg/mL, binding of biotinylated
HFt to Ba/F3.hTfR1 was saturable, and at all concentrations it was
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inhibited by unconjugated HFt, which shows that binding was spe-
ciﬁc (Fig. 1C). Furthermore, an mAb to TfR1,M-A712, completely
blocked the binding of HFt to TfR1, conﬁrming that binding was
mediated by TfR1 (Fig. 1C). Additionally, CHO cells lacking an
endogenous TfR (TRVb cells) (24) bound only low levels of HFt,
but this was notably enhanced inCHOcells expressing humanTfR1
(TRVb1 cells) and this enhanced binding was blocked by anti-TfR1
mAb (Fig. 1D). These studies show thatTfR1bindsHFt, but they do
not exclude the possibility that other proteins might be required for
this interaction. We, therefore, examined the interaction between
TfR1 and HFt in isolation by coupling soluble his-tagged TfR1
extracellulardomain to cobalt beads, using these to assess bindingby
HFt. In these studies, HFt showed low levels of nonspeciﬁc binding
to the beads in the absence of TfR1, but the addition of TfR1
markedly enhanced binding ofHFt, which conﬁrms that TfR1 binds
HFt in the absence of other proteins (Fig. 2A). By similar methods,
we have found that horse spleen apoferritin also binds to TfR1 (25).
Effects of HFE and Tf on Binding of HFt to TfR1. The hemochroma-
tosis protein HFE binds tightly to TfR1, reducing binding of
transferrin (26). In our pull-down studies, HFE in 10 molar excess
had little or no effect on the binding of HFt to soluble TfR1, as
shown in Fig. 2A, where HFE reduced recovery of HFt only slightly
and in proportion to the recovery of TfR1. Thus, under the con-
ditions of our studies, HFE does not signiﬁcantly impair binding of
HFt to TfR1.
For studies regarding competition betweenTf andHFt for TfR1,
we returned to studies of intact cells (MOLT-4Tcells), because they
havebeen shown to speciﬁcally bindHFt.Weconﬁrmed this byﬂow
cytometry, showing that binding of biotinylated HFt to MOLT-4
cells is blocked by unconjugated HFt, but it is not blocked by LFt,
indicating that HFt binding is speciﬁc and conﬁrming that LFt does
not share the binding characteristics of HFt (Fig. S2). We then
assessed the effect of HFt on binding by 125I-labeled diferric Tf to
MOLT-4 cells. With 125I-Tf at 5 × 10−9 M, binding was blocked as
expected by unlabeled diferric Tf, but HFt in 20-fold molar excess
blocked binding by diferric Tf less than 50% (Fig. 2B). We also
attempted to test the reverse, the blocking of 125I-labeled HFt by
diferric Tf, and to use binding by 125I-labeled HFt to perform
Scatchard plot analysis of HFt binding; however, these experiments
werenotpossible, because 125I-labelingofHFtbyeither theBolton–
Hunter method or the use of Iodobeads resulted in loss of speciﬁc
binding toTfR1.As assessedbyﬂowcytometry, however, binding by
50 nMHFt toMOLT-4 cells was reduced by as little as 6 nMdiferric
Tf, but evenwith very high levels of Tf (500 nM), inhibitionwas only
partial, reaching a maximum of ∼70% inhibition (Fig. 2C). The
inability of diferric Tf to fully block binding by HFt does not likely
reﬂect a second receptor forHFt onMOLT-4 cells, becausemAb to
TfR1 completely blocks binding ofHFt to these cells (Figs. 3 and 4).
Although inhibition by Tf of HFt binding to TfR1 is incomplete, it
again shows the speciﬁc binding ofHFt to TfR1, and it excludes the
possibility that this binding is mediated or facilitated by Tf.
Binding of HFt to TfR1 Permits Entry of HFt into Endosomes and
Lysosomes. Because diferric Tf incompletely blocks binding byHFt,
we were able to use ﬂuorescence microscopy to examine the
simultaneousbinding anduptakeofdiferricTf andHFt byMOLT-4
cells. Consistent with results obtained by ﬂow cytometry, binding of
HFt to MOLT-4 cells on ice was blocked by anti-TfR1, whereas
binding of Tf was not (Fig. 3, top two panels; Fig. S3 shows mag-
niﬁcation of Fig. 3). On warming of the cells to 37 °C, HFt and Tf
were both rapidly internalized. At early time points, much of the
HFt colocalized with Tf, which is known to be restricted to endo-
somes (Fig. 3). Unlike Tf, however, HFt was also transferred to
Fig. 1. Identiﬁcation of TfR1 as a receptor for HFt.
(A) Example of a clone obtained by transducingmouseBa/
F3 cells with a cDNA library from human 721.221 cells and
staining with human HFt (Upper) or anti-TfR1 (Lower).
(B) Transduction of Ba/F3 cells with cDNA for TfR1 alone
allows expression of TfR1 (Lower) and binding of HFt
(Upper). (C) Binding ofHFt to Ba/F3 cells expressing TfR1 is
saturable (•) and is inhibited either by excess HFt (△) or
mAb to TfR1 (○). (D) HFt binds to TRVb1 cells, which
express TfR1 (•), and binding is inhibited bymAb to TfR1
(○). Low levelsofbindingare seen inTRVb cells,which lack
TfR1 (▲), and this binding is not blockedbyanti-TfR1 (△).
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lysosomes, which was assessed by colocalization with Lamp1 (Fig.
3). We conclude that HFt can dissociate from TfR1 in endosomes,
allowing for the translocation of HFt to lysosomes.
TfR1 Accounts for Most of the Binding of HFt to Cell Lines, Activated
Lymphocytes, and Reticulocytes. We next examined the role of
TfR1 in binding of HFt to different cell lines, using the capacity of
the anti-TfR1mAbM-A712 to speciﬁcally block binding ofHFt to
TfR1. The cell lines examined includedMOLT-4 T cells andK562
myeloid/erythroid leukemia cells, both of which have been pre-
viously shown to bind HFt (12, 13). All of the lines examined
expressed TfR1 (Fig. S4), and all bound HFt (Fig. 4). Binding of
HFt to all of the cell lines was substantially blocked by anti-TfR1;
in MOLT-4 cells, it was blocked almost completely (Fig. 4). K562
cells have previously been used to show up-regulation of trans-
ferrin receptors after iron depletion by desferrioxamine (27). We
conﬁrmed that TfR1 was up-regulated on K562 cells after treat-
ment with desferrioxamine, and we found that this was accom-
panied by increased binding of HFt (Fig. S5). We conclude that
prior descriptions of HFt binding byMOLT-4 and K562, as well as
binding by the other cell lines tested, can be attributed largely, if
not entirely, to their expression of TfR1.
Prior studies have shown saturable binding of HFt to activated
lymphocytes (16, 17). In our studies, fresh, unactivated T cells
expressed only low levels of TfR1 and did not bind detectable
levels of HFt (Fig. 5ALeft); however, after 60 h of stimulation with
the mitogen phytohemagglutinin (PHA), levels of TfR1 were
increased, binding of HFt was detected, andmostHFt binding was
blocked by mAb to TfR1 (Fig. 5B Left). Thus, binding of HFt to
mitogen-activated T cells reﬂects up-regulation of TfR1.
Similarly, fresh B cells expressed only low levels of TfR1 (Fig. 5A
Right). They also bound low levels of HFt, but this binding was not
blocked by anti-TfR1 (Fig. 5A Lower Right). After stimulation of
peripheral blood mononuclear cells with PHA, B cells expressed
increased TfR1 in the samemanner as T cells, presumably because
of the release of cytokines by activated T cells; these B cells bound
HFt, and most binding was inhibited by anti-TfR1 (Fig. 5B Lower
Right). Thus, activated B cells, as well as T cells, bind HFt by up-
regulating TfR1.
Blood cells from one volunteer included a population of non-T,
non-B cells that expressed high levels of TfR1 and that bound high
levels ofHFt. These cells lackedCD45 but expressed glycophorinA,
indicating that they were erythroid cells; staining of these cells with
new methylene blue after sorting conﬁrmed that they were retic-
ulocytes that had copuriﬁed with PBMC. About 30% of these gly-
cophorinA+/CD45- cells expressedhigh levelsofTfR1, anda similar
percent boundHFt in amanner that was blocked by anti-TfR1 (Fig.
5C). Prior studies have shown that erythroid precursors bind and
take up ferritin (11, 28) and that this can provide sufﬁcient iron for
the production of Hb (18, 19). Our ﬁndings show that the binding of
HFt to reticulocytes is speciﬁcally and uniquely mediated by TfR1.
Discussion
Our studies show that TfR1 serves as a receptor for HFt. Binding
occurs in the absence of Tf or HFE and is signiﬁcantly inhibited by
diferric Tf, although not completely. TfR1 accounts formost of the
binding of HFt to all cell lines that we have studied, as well as to
mitogen-stimulated blood lymphocytes and fresh reticulocytes.
After binding to TfR1, HFt enters not only endosomes but also
lysosomes. Other studies have shown that cytoplasmic ferritin sim-
ilarly reaches lysosomes and that lysosomes may facilitate the
release of iron from ferritin (29, 30). De Domenico et al. (31)
recently showed that lysosomal degradation of cytosolic ferritin can
be by induced by autophagy. Alternatively, cytosolic ferritin can be
ubiquitinated and subjected to proteasomal degradation (3, 31, 32).
It will be of interest to deﬁne the fate of HFt after it reaches lyso-
somes after endocytosis through TfR1, as well as the fate of iron
contained within the HFt.
Konijn and coworkers (18, 19) have shown that erythroid pre-
cursors can internalize and use iron from HFt in the production of
Hb, and this process is blocked by inhibitors of endocytosis (18, 19).
Our studies show that the binding of HFt to fresh reticulocytes is
dependent on TfR1 and that TfR1 mediates endocytosis of HFt as
well as diferric Tf. It is, thus, highly likely that binding of HFt to
TfR1onerythroid precursors is required for its use in supplying iron
for erythropoiesis.
Anti-TfR1 blocks binding of HFt but not diferric Tf to TfR1,
suggesting that the binding sites for HFt and Tf may not be identical.
Nonetheless, diferric Tf inhibits binding of HFt to TfR1, indicating
either that the binding sites for HFt and Tf overlap or that Tf alters
TfR1 in a way that reduces binding by HFt. Reciprocally, high con-
centrations ofHFt partially block binding by diferric Tf to TfR1. This
likely explains the observation by Tsunoo and Sussman (33) over 25
years ago that humanplacental ferritin or horse splenic ferritin inhibit
binding of Tf to placental extracts. We did not observe a signiﬁcant
effect of HFE on binding by HFt to TfR1, unlike its known effect on
bindingbyTf (26, 34). Importantly, neitherHFEnorTf is required for
bindingbyHFt toTfR1; bindingofHFt toTfR1occurs in theabsence
Fig. 2. Binding of HFt to TfR1 and effects of HFE and Tf. (A) HFt in solution
binds to isolated TfR1, and this is not signiﬁcantly inhibited by HFE. Lanes 1, 3,
4, 6, 7, and8 showSDS/PAGEof proteins eluted fromcobalt beads treatedwith
His-tagged TfR1 only (lane 1), HFE only (lane 3), His-tagged TfR1 followed by
HFE (lane 4), HFt only (lane 6), His-tagged TfR1 followed by HFt (lane 7), and
His-tagged TfR1 followed by HFE and HFt (HFE:HFt molar ratio = 10:1; lane 8).
Lanes 2 and 5 showHFE andHFt, respectively, not exposed to beads but placed
directly on the gel. (B) Binding of 125I-Tf to MOLT-4 cells is only partially
inhibited by 100× molar excess of HFt (□) and not at all by antibody to TfR1
(■). As a control, binding is inhibited by unlabeled Tf (•). (C) Binding of
biotinylated HFt (50 nM) toMOLT-4 cells is inhibited by Tf (•), but inhibition is
incomplete, even with a 10-fold molar excess of Tf.
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of either. HFt consists of 24 identical subunits, and TfR1 consists of
two identical subunits, so the interactions between these proteins on
the cell surface may be complex. We were not able to perform
Scatchardanalysis of bindingby 125I-HFt, because iodination reduced
binding ofHFt toTfR1; however, other approacheswill be of interest
to examine this interaction.
The selective binding by TfR1 of HFt, not LFt, is consistent with
prior observations that cell lines and hematopoietic cells selectively
bind HFt (12–17). In this regard, it may be noteworthy that the
proinﬂammatory cytokines TNFα and IL-1α selectively induce
transcription of FHC but not FLC through induction of the tran-
scription factorNFkB, thereby increasing the content of the FHC in
ferritin (5). Although an increase in circulating FHC in inﬂamma-
tion has not yet been directly shown, the induction of FHC by
inﬂammatory cytokines suggests the possibility that FHCmay serve
as a secondary signal in inﬂammation. Studies to test this can now
focus in particular on TfR1.
BecauseTfR1 seems to bindHFt but not LFt, our ﬁndings do not
explain prior evidence that human liver cells can bind LFt as well as
HFt (17), and this receptor remains tobe identiﬁed. Inmice,Li et al.
(35) recently identiﬁed Scara5 as a receptor for LFt in the devel-
oping kidney and showed that this accounted for iron uptake in the
absence of TfR1 or TfR2. However, Scara5 is not expressed in liver
(36), and human orthologs have not yet been described.
Inmice, we previously identiﬁed Tim-2 as a receptor forHFt, but
Tim-2 is not expressed in humans (21). Interestingly, we have so far
found no evidence that murine HFt or humanHFt binds to murine
TfR1, suggesting that thesemechanisms for recognitionofHFthave
diverged between humans and mice. The extracellular domains of
mouse and human TfR1 protein are 76% identical at the protein
level (86% conserved), but areas of nonhomology are found
throughout these domains.We have not yet studied binding byHFt
to the more distantly related (but still 46% identical) TfR2.
Of particular relevance to our studies, Li et al. (37) have recently
shown that the human chemokine receptor CXRC4 binds cytosolic
FHCinamanner that isdependenton the serinephosphorylationof
FHCat position 178. In cells overexpressingCXCR4, its interaction
with cytosolic FHC is increased by the internalization of CXCR4
after binding by its ligand CXCL12, and FHC inhibits activation of
ERK1/2 by CXCL12 in these cells (37). This may relate to prior
observations byPhamet al. (38) that showed that FHC inhibits JNK
activation by inhibiting ROS. It will be important to determine if
HFt imported through the TfR1 can reach the cell compartments
where it could contribute to these effects.
The shared use of TfR1 to bind and internalize both Tf and HFt
suggests that this pathway may serve to coordinate the uptake and
useof ironby these two ligands.Tfbinds ferric iron (Fe3+),but in the
endosomes of erythrocyte precursors, this is reduced to ferrous iron
(Fe2+) by ferroreductases, notably Steap3 (39, 40). Thus, ferrous
iron would be available for uptake by HFt in endosomes. We have
not observed this in preliminary studies, but further studies are in
progress. Alternatively, or perhaps additionally, Tf and HFt may
serve as redundant mechanisms for the uptake of iron by cells.
Materials and Methods
Cell Culture. MOLT-4, K562, 721.221, U937, HeLa, and 293T cells were obtained
from the American Type Culture Collection, and Ba/F3 cells were provided by
Lewis Lanier. These cell lines were grown in RPMI-1640 medium (Mediatech,
Manassas,VA), or for 293T cells, DMEM (Cellgro). All mediawere supplemented
with10%FBS (AtlanticBiologics) andpenicillin-streptomycin-glutamine(Gibco).
Growth of Ba/F3 cells was sustained by adding 1 ng/mL IL-3 (BD Biosciences).
TRVb and TRVb1 cells (24), provided by Timothy E. McGraw, Weill Cornell
Fig. 3. Binding of HFt to TfR1 results in endocytosis of HFt and trafﬁcking of
HFt to lysosomes inMOLT-4 T cells. MOLT-4 cells were incubated for 60min on
ice with HFt-Alexa 568 (50 μg/mL) and Tf-Alexa 488 (50 μg/mL). During this
period, both HFt and Tf bound to the cell surface (top row), but anti-TfR1 (50
μg/mL) blocked the binding of HFt but not Tf (second row). Cells were sub-
sequently incubated at 37 °C for 2–120 min, followed by staining with the
lysosomal marker Lamp1. The examples presented include enlargements of
one or two selected cells, boxed to the right side of each frame, and des-
ignated by the white arrow in frame A for each time point. At 2 min, HFt
appeared in early endosomes, as shown by colocalization with Tf (2 min; E),
but even at this early time point, HFt was also found in lysosomes, as shown by
colocalizationwith Lamp1 (2min; F). At 30min, themajority of HFtwas found
primarily in lysosomes, and only little was seen in early endosomes (30 min;
cell at top right); however, in some cells, HFt was still in early endosomes as
well as lysosomes (30 min; cell at lower right). At 120 min, some HFt was still
seen in endosomes or lysosomes, but HFt was also seen in vesicles that lacked
Lamp1 or Tf, presumably endosomes from which Tf has been sorted
(120 min; E and F). As expected, and in contrast to HFt, Tf did not sort into
lysosomes (2 min to 120 min; G). (Scale bar: 10 μm.)
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MedicalCollege,NewYork,NY,weremaintained inHam’s nutrient F12medium
(Invitrogen) supplementedwith 5%FBS andpenicillin-streptomycin-glutamine.
To test the effects of iron chelation, K562 cells were incubated for 18 h with
desferrioxamine (Sigma) in concentrations ranging from 2 to 50 μM.
Expression Cloning of the Human HFt Receptor. The retroviral cDNA library
from 721.221 human B cells was generated by using methods previously
described (41). The library was transfected into Phoenix cells by FuGENE 6
(Roche Applied Science). The virus-containing supernatant was collected 48
h later and used to infect Ba/F3 cells with N-[1-(2,3-Dioleoyloxy)propyl]-N,N,
Ntrimethylammoniummethylsulfate (DOTAP) liposomal transfection reagent
(10 μg/mL; Roche Applied Science). Two days later, Ba/F3 cells were stained
with biotinylated human HFt plus streptavidin APC (SA-APC; Caltag) and
selected by cell sorting. This enrichment was repeated ﬁve times, after which
>90% of the cells stained with HFt. The genomic DNA was isolated (Qiagen),
and PCR was carried out by using an advantage-GC genomic PCR kit (Clon-
tech) with the primers 5′-GGT GGA CCA TCC TCT AGA CT-3′ (sense) and 5′-
TTT ATT TTA TCG TCG ATC GAC C-3′ (antisense).
Cellular Expression of Human TfR1. TfR1 cDNA was obtained from the ATCC
and conﬁrmed by sequencing. The cDNA was ampliﬁed by PCR, cloned into
the pMX-puromycin expression vector (Lewis Lanier, University of California
San Francisco, CA), and transfected into Phoenix packaging cells using
Fugene 6 (Roche). Two days later, the viral supernatant was harvested and
used to infect Ba/F3 cells with the use of DOTAP (10 μg/mL; Roche). Clones
were selected and maintained in RPMI-1640 plus 1 μg/mL puromycin (Sigma).
Preparation and Puriﬁcation of Soluble Proteins. Human HFt and LFt were
produced in Escherichia coli and puriﬁed as described (42). Horse spleen
apoferritin was from Calbiochem. HFE and His-tagged soluble TfR1 were
produced as previously described (43). Diferric Tf was from Sigma.
Isolation and Culture of Human PBMC. Peripheralbloodmononuclearcellswere
isolated from blood of normal human donors by Ficoll-hypaque gradient
centrifugation (Amersham Biosciences) using a protocol approved by the
University of California San Francisco and San Francisco Veterans Affairs
Medical CenterCommitteesonHumanResearch. Cellswere cultured for60h in
RPMI 1640 with 10% FBS in the presence of 10 μg/mL PHA. GlycophorinA+/
CD45− cells were isolated byﬂow cytometry using a FACSAriaﬂow cytometer.
Flow Cytometry. Monoclonal antibodies were from BD Bioscience, unless
otherwise indicated, and they included: mouse anti-human CD3 (clone
UCHT1, FITC), mouse anti-human CD19 (clone HIB19, FITC), mouse anti-
human CD45 (clone H130, PerCP-Cy5.5; eBioscience), mouse anti-human
glycophorin A (clone GA-R2, FITC), mouse anti-human TfR1 (clone M-A712,
phycoerythrin, or biotinylated). Human HFt and LFt were biotinylated by a
using EZ-Link sulfo-NHS-LC-biotin kit (Pierce) according to the manufacture’s
directions. Fresh PBMC or PHA-stimulated PBMC was stained with bio-
tinylated HFt (20 μg/mL) with or without the presence of anti-TfR1 (50 μg/
mL), and binding was detected with streptavidin coupled to allophycocyanin
(APC) ﬂuor. Expression of the human TfR1 was assessed by using PE-con-
jugated anti-TfR1 or as indicated, biotinylated anti-TfR1. Binding to cell lines
of biotinylated HFt or anti-TfR1 was detected by streptavidin-APC (SA-APC).
Cells were analyzed on a FACSCalibur ﬂow cytometer (BD Biosciences). Data
were displayed and analyzed by using FlowJo software.
Pulldown Assay. Soluble His-tagged TfR1 (100 μg, 0.715 nmol) was allowed to
bind to 50 μL of cobalt chelate resin (Profound Pull-Down Poly-His Protein:
Protein Interaction Kit; Pierce) following the procedure of the manufacturer.
TfR1-conjugated beads or unconjugated beads were exposed to 90 μg HFt
(0.176 nmol) for 90 min at 4 °C, with or without 78.5 μg HFE (1.76 nmol). The
beads were washed, and proteins were eluted in 100 μL 290 mM imidazole,
which was followed by analysis with SDS/PAGE.
Assays for Cross-Blocking by Tf, HFt, and LFt. 125I-labeled human diferric Tf,
labeled by a modiﬁcation of the Hunter and Greenwood methods, was pur-
chased from PerkinElmer Life Sciences. Before binding of labeled Tf, 5 × 105
MOLT-4 cells were incubated for 30 min on ice with 100 μL saline or with cold
HFt or Tf (Sigma) at concentrations ranging from 0.27 to 200 nM. 125I-labeled
Tf was added in equal volume to a ﬁnal concentration of 5 nM, and cells were
incubated on ice for 90 min. Cells were then washed three times in PBS and
suspended inPBS fordetectionofbound 125I. The capacityof Tfor LFt to inhibit
binding by HFt was assessed by ﬂow cytometry: 5 × 105 MOLT-4 cells were
incubated for 30–90 min on ice with biotinylated HFt (50 nM) together with
unlabeled Tf at concentrations from 0.07 to 500 nM, or with unlabeled LFt at
Fig. 4. Anti-TfR1 mAb blocks binding by HFt to six human cell lines: K562
(erythroleukemia),MOLT-4 (T cell), 721.221 (Bcell),U937 (monocyte/macrophage),
HeLa (ovarian cancer), and293T cells (kidney). The y axis showsmeanﬂuorescence
intensity (MFI) of staining with biotinylated HFt/streptavidin.
Fig. 5. HFtbinds toTfR1onactivated lymphocytes and reticulocytes. (AUpper)
Fresh, unstimulatedperipheral bloodT cells (CD3+; Left) express little if any TfR1
(blue line),whereas freshB cells express low levels (CD19+;Right). In theseandall
stains with anti-TfR1, the control is staining with an isotype-matched mAb
(shaded curve). (Lower) HFt does not bind to fresh T cells (CD3+; Left). The blue
line represents staining by biotinylated HFt plus SA-APC. The gold line indicates
staining by HFt in the presence of anti-TfR1. The shaded curve is SA-APC only.
BindingofHFt to freshB cells canbedetected (CD19+,blue line;Right), but this is
not blocked by anti-TfR1 (gold line). (B Upper) After exposure to PHA, both
Tcells (CD3+;Left) andBcells (CD19+;Right) up-regulateTfR1(blue line). (Lower)
After activation, both B and T cells bind HFt (blue line), andmuch, but not all, of
this binding is blocked by anti-TfR1 (gold line). (C) In a normal donor, glyco-
phorin A+CD45- reticulocytes were coisolated with PBMC. About 30% of these
expressed high levels of TfR1 (Left). A similar percentage of cells bound HFt at
high levels (blue line; Right), and binding was blocked by anti-TfR1 (gold line;
Right) or 100-fold excess of unlabeled HFt (light blue line; Right).
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concentrations from 5 to 500 nM. Cells were washed, and HFt was detected
with SA-APC.
Deconvolution Fluorescence Microscopy of Endocytosis. HFt was labeled with
Alexa 568 (Invitrogen) according to the manufacture’s instructions. Internal-
izationofHFtbyMOLT-4T cellswasperformedaspreviouslydescribed formouse
cells (21). Brieﬂy, MOLT-4 cells were incubated for 30 min at 37 °C in PBS sup-
plementedwith 10mMTris-HCl, 10mMHepes, 5mMglucose, and 1mg/mLBSA
at pH 7.4. Cells were pelleted and resuspended in cold buffer with or without
anti-TfR1 mAb (50 μg/mL), and then they were incubated on ice for 30 min,
whichwasfollowedby theadditionofHFt-Alexa568 (50μg/mL)andTf-Alexa488
(50 μg/mL; Invitrogen); further incubation was on ice for 90min. Cells were then
washedwithcoldPBSand resuspended inbufferat37 °C toallowendocytosis. At
deﬁned time points, internalization was stopped by adding cold PBS/0.02%
sodium azide. Cells were pelleted and resuspended in 4% paraformaldehyde,
and they were plated on poly-L-lysine–treated coverslips (BD Biosciences) for 60
min. Cells were permeabilizedwith 0.5% Triton X-100 in PBS for 5min and then
blocked with 0.5% BSA and 0.1% Triton X-100 in PBS for 30 min at room tem-
perature. To identify lysosomes, cells were incubated with an anti-Lamp1 mAb
(1:200, clone H4A3; Invitrogen) overnight at 4 °C. Cells were then washed three
timeswith PBS and incubatedwith goat anti-mouse IgG1 conjugatedwithAlexa
647 (1:500; Invitrogen). Images were collected by an API DeltaVision DV3
Restoration microscope using a MicroMax 5 MHz cooled CCD camera (Roper
Scientiﬁc); deconvolution was performed using API SoftWoRx software.
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